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Cytokine-based mobilization in light chain (AL) amyloidosis is frequently complicated by ﬂuid overload,
weight gain, cardiac arrhythmias, and peri-mobilization mortality. We analyzed hematopoietic progenitor
cells (HPC) mobilization outcomes in 49 consecutive AL amyloidosis patients at our institution between 2004
and 2013 with granulocyte colonyestimulating factor (G) (10 mg/kg/day) (n ¼ 25) versus an institutional
protocol to limit G exposure using plerixafor (P) (.24 mg/kg s.c. starting day 3 of G 10 mg/kg) (n ¼ 24). GþP
strategy yielded higher total CD34þ cells/kg (12.8  106 versus 6.3  106; P < .001) and CD34þ cells/kg
collected on day 1 (10.8  106 versus 4.9  106, P ¼ .004) compared with the G cohort. More GþP patients
collected 5  106 CD34þ HPCs/kg (22 versus 16, P ¼ .02) and  10  106 CD34þ HPCs/kg (13 versus 5,
P ¼ .01). Four patients (16%) had mobilization failure with G; none with GþP. Peri-mobilization weight gain
was lower with GþP strategy (median weight gain 1 versus 7 pounds, P ¼ .009). Numbers of apheresis
sessions (median, 1 versus 1, P ¼ .52), number of hospitalization days (median, 1.1 versus 1.6, P ¼ .52),
transfusions, use of intravenous antibiotics, and cardiac arrhythmias were similar. In conclusion, our study
demonstrates that upfront use of GþP as a mobilization strategy results in superior HPC collection, no
mobilization failures, and less weight gain than G alone.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION centers that adhere to careful patient selection [7]. In this
Immunoglobulin light chain (AL) amyloidosis is a
monoclonal plasma cell proliferative disorder that is char-
acterized by tissue deposits of misfolded light chains lead-
ing to organ damage [1]. High-dose melphalan with
autologous hematopoietic cell transplantation (auto-HCT)
can provide deep hematological responses, reversal of
amyloid-related organ dysfunction, and sustained disease
control in a subset of ﬁtter AL amyloidosis patients [2-4].
Despite its promise, treatment with this modality has so far
been limited by high treatment-related mortality for many
patients, owing to high morbidity from amyloid organ
involvement [5,6]. Recent trends have shown improved
outcomes of auto-HCT in experienced transplantationedgments on page 1930.
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ty for Blood and Marrow Transplantation.setting, auto-HCT can provide durable disease control in
patients with AL amyloidosis [8-10].
Although the collection of peripheral blood hematopoi-
etic progenitor cells (HPC) in hematologic malignancy
patients is generally associated with minimal morbidity, this
is not true for AL amyloidosis patients. Chemotherapy-based
mobilization in AL amyloidosis has largely been abandoned
because of the high risk of cardiac events, infections,
bleeding complications, and mortality [11-13]. Hence, by
default, the use of granulocyte colonyestimulating factor
(G-CSF) for HPC mobilization has become the standard
method for mobilization in AL amyloidosis [14]. However,
signiﬁcant morbidity, including deaths, have been reported
during or immediately after G-CSFebased mobilization in AL
amyloidosis patients [15-17]. Complications during
G-CSFeinduced HPC mobilization in AL amyloidosis patients
(especially with cardiac involvement) have included ﬂuid
overload, splenic rupture, signiﬁcant weight gain,
cardiac arrhythmias, and cardiopulmonary decompensation
Table 1
Baseline Characteristics
Characteristic Mobilization Strategy P Value
G (n ¼ 25) GþP (n ¼ 24)
Age at diagnosis, median
(range), yr
56.6 (30-75) 56.9 (44-71) .34
Male gender 11 (44%) 12 (50%) .67
Race
Caucasian 20 (80%) 19 (80%) 1.00
African American 5 (20%) 5 (20%)
Organ Involvement*
Cardiac 16 (64%) 16 (67%) .84
Renal 17 (68%) 18 (75%) .58
GI 11 (44%) 6 (25%) .16
Cardiac biomarkers at
diagnosis
Troponin T, median
(range)
.3 (0-1.3) 0 (0-.3) <.001
NT pro BNP; median
(range)
584 (37-8000) 594 (42-18000) .51
Cardiac stage .24
I 6 (24%) 6 (25%)
II 6 (24%) 13 (54%)
III 7 (28%) 5 (21%)
Missing 6 (24%) 0
Creatinine at diagnosis,
median (range), g/dL
1.1 (.6-4.2) 1 (.5-4.5) .68
Involved free light chain
Kappa light chain 7 (28%) 5 (20%) .56
Lambda light chain 18 (72%) 19 (79%)
KPS, median (range) 90 (60-100) 90 (60-100) .05
Pretransplantation BM
cellularity, median
40 (10-80) 40 (10-80) .64
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presence of concomitant autonomic dysfunction can exac-
erbate blood pressureerelated issues, making it difﬁcult to
maintain proper ﬂuid balance [18]. In fact, signiﬁcant weight
gain during HPC collection has been shown to be an inde-
pendent predictor of mortality after auto-HCT [19]. In addi-
tion, HPC collection failure rates, in otherwise
transplantation-eligible AL amyloidosis patients, with a
cytokine-only approach ranges from 5% to 10% [20], under-
scoring the need for safer andmore effective methods of HPC
collection in this high-risk patient cohort.
Plerixafor, a selective and reversible antagonist of C-X-C
chemokine receptor type 4 has proven efﬁcacy in collecting
peripheral blood HPCs via the reversible blockade of stromal
cell derived factor 1 and C-X-C chemokine receptor type 4
[21]. Its efﬁcacy in combination with G-CSF has been
demonstrated primarily in the context of multiple myeloma
and non-Hodgkin lymphoma, where it has been used both
alone and in combination with G-CSF [22,23]. However,
plerixafor-based strategies have not been explored in AL
amyloidosis as a ﬁrst-line mobilization method. Because of
signiﬁcant weight gain, peri-mobilization morbidity, and
HPC collection failure at our center with G-CSFeonly mobi-
lization, we explored the upfront use of a plerixafor-based
collection strategy to minimize peri-mobilization morbidity
and collection failures. Herein, we report the ﬁrst upfront
mobilization outcomes with plerixafor þ G-CSF method
compared with G-CSF alone.(range), %
Pretransplantation BM
core plasma cell,
median (range), %
10 (0-40) 10 (0-80) .19
Organ involvement, 3 14 (56%) 7 (29.2%) .20
Cardiac organ responsey .43
Yes 4 5
No 4 10
N/Az 17 9
Renal organ responsex .28
Yes 0 4
No 4 13
N/Az 21 7
Prior therapiesk
Bortezomib 
cyclophosphamide
4 (16%) 23 (95%) <.01
Lenalidomide 1 (4%) 2 (8.3%) .60
None 15 (60%) 1 (4.2%) <.001
Other{ 9 (36%) 2 (8.3%) .020
Lines of prior therapies, 0 (0-4) 1 (0-3) <.001METHODS
Patient Population
All patients with a histologically conﬁrmed diagnosis of AL amyloidosis
undergoing HPC mobilization at our center from 2004 to 2013, with intent
for upfront auto-HCT were included. This study was approved by the
institutional review board at the Medical College of Wisconsin.
Between 2004 and 2008, all patients underwent HPC mobilization with
G-CSF alone administered s.c. daily at 10 mg/kg of actual patient body weight.
Apheresis was started on day 5 of G-CSF administration. Apheresis and G-
CSF injections were continued daily for up to 4 consecutive collections or
until a target yield of at least 5  106 CD34þ cells/kg actual patient body
weight, whichever occurred ﬁrst. Beginning in October 2009, as a quality
improvement institutional initiative to reduce G-CSF exposure and associ-
ated complications during HPC collection, mobilizationwas modiﬁed to add
plerixafor at .24 mg/kg s.c. on the evening of day 3 of G-CSF (10 mg/kg)
administration, approximately 11 hours before the initiation of apheresis.
No adjustment in the dose of plerixafor was made in patients with renal
insufﬁciency.median (range)
Pretransplantation status#
CR þ VGPR 1 (4%) 8 (33%) <.001
PR 2 (8%) 10 (41%)
<PR 7 (28%) 5 (21%)
N/A 15 (60%) 1 (4.2%)
NT pro BNP indicates N-terminal pro-brain natriuretic peptide; KPS, Kar-
nofsky performance score; BM, bone marrow; N/A, not available; CR, com-
plete remission; VGPR, very good partial response; PR, partial response.
* Percentages do not add up 100% because some patients hadmore than 1
organ involved.
y Heart: mean interventricular septal thickness decreased by 2 mm, 20%
improvement in ejection fraction, improvement by 2 New York Heart As-
sociation classes without an increase in diuretic use and no increase in wall
thickness.
z Not applicable: either no pre-HCT induction given or no renal or cardiac
involvement at baseline.
x Kidney: 50% decrease (at least .5 g/day) of 24-hour urine protein (urine
protein must be >.5 g/day pretreatment). Creatinine and creatinine clear-
ance must not worsen by 25% over baseline.
k Percentages do not add up 100% as some patients received multiple
lines of treatment.
{ Other regimens include melphalan, thalidomide, and dexamethasone.
# Version 2.2014, 10/4/2013 NCCN.Apheresis Procedure and Targets
All collections were performed in the outpatient setting using the
mononuclear cell program on the COBE Spectra apheresis (Terumo BCT,
Lakewood, CO) system by processing 3 to 4 blood volumes. It is the insti-
tutional policy at our transplantation center to collect a minimum of
2  106 CD34þ cells/kg with a target of 5  106 CD34þ cells/kg in AL
amyloidosis patients. Determination of CD34þ cells count of the apheresis
product was performed at the Blood Center of Wisconsin Laboratory. The BD
FACSCanto II ﬂow cytometer (Becton Dickinson, San Jose, CA) was used for
all analyses. Red blood cell lysed and washed samples were used for CD34þ
enumeration with PE-labeled, 8G12 clone, immunoglobulin G1 (Becton
Dickinson) based on International Society of Hematotherapy and Graft En-
gineering guidelines [24]. The ﬁnal products were cryopreserved in 10%
DMSO using controlled rate freezer and then stored in liquid nitrogen.
All patients were closely monitored in the outpatient apheresis unit for
any complications that occurred during the mobilization. All other elements
of the mobilization process (eg, the target CD34 dose, blood volume pro-
cessed during apheresis, and supportive care procedures) were identical
between the 2 groups. Monitoring included daily body weights, vital signs,
pulse oximetry, physical examination for signs of ﬂuid overload, and docu-
mentation of blood product administration, infectious complications, elec-
trolyte imbalances, and cardiac rhythm abnormalities.
Table 2
Mobilization and Apheresis Results
Mobilization Parameters G (n ¼ 25) GþP (n ¼ 24) P Value
CD34þ cells  106/kg collected
on day 1, median (range)
3.6 (.1-13) 7.1 (1.9-27.4) .012
Patients collecting 2  106
CD34þ cells/kg on day 1, n (%)
17 (68%) 22 (92%) .07
Patients collecting 5  106/kg
on day 1
11 (44%) 15 (62%) .19
Total CD34þ cells  106/kg
collected, median (range)
6.1 (.7-13) 11.9 (2.6-27.4) <.001
Patients collecting 5  106
CD34þ cells/kg total, n (%)
16 (64%) 22 (92%) .02
Patients collecting 10  106
CD34þ cells/kg total, n (%)
5 (20%) 13 (54%) .013
Mobilization failures*, n (%) 4 (16%) 0 (0%) .11
Total number of apheresis
sessions, median (range)
1.0 (1.0-4.0) 1.0 (1.0-3.0) .52
Weekend apheresis 1 (4%) 0 .45
Number of G-CSF doses given,
median (range)
6 (5-8) 5 (4-6) <.0001
P values in bold text are statistically signiﬁcant.
* Mobilization failure deﬁned as a total CD34þ cell yield of <2  106
CD34þ cells/kg.
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All patients who underwent transplantation received conditioning with
melphalan (100 to 200 mg/m2) on day 2, followed by infusion of autolo-
gous peripheral blood HPC on day 0. Growth factors were not used uni-
formly after transplantation to hasten neutrophil recovery. All patients
received fungal (ﬂuconazole), herpes zoster/herpes simplex (acyclovir or
valacyclovir), and bacterial prophylaxis (ciproﬂoxacin) per institutional
guidelines. The time of neutrophil engraftment was considered the ﬁrst of 3
consecutive days with absolute neutrophil count .5  109/L after post-
transplantation nadir. The time of platelet engraftment was considered
the ﬁrst of 3 consecutive days with platelet count 20  109/L, in the absence
of platelet transfusion for preceding 7 days.
Statistical Analysis
Patient demographics and mobilization outcomes between the 2 groups
were compared byWilcoxon rank-sum test and chi-square test. Kaplan-Meier
plots were used to display survival times, and because no events were
observed in the G-CSF and plerixafor mobilization group, the Fisher exact test
was used to compare overall survival at 12 months among those with at least
12months of follow-up. The cumulative incidence functionwas used to assess
neutrophil and platelet recovery or relapse and a normal Z-test was used to
compare incidence (at 30 days for count recovery, 24 months for relapse).
Successful mobilizationwas deﬁned as a total yield of at least2106 CD34þ
cells/kg patient body weight in the ﬁnal product. To account for the differ-
ences in the number of collection days across patients, data regarding CD34þ
stem cell collection on day 1 were also analyzed. The analysis was performed
using SAS version 9.3 (SAS Institute, Cary, NC).Table 3
Perimobilization Toxicity and Supportive Care
Toxicity G (n ¼ 25) GþP (n ¼ 24) P Value
Neutropenia fevers* 0 1 (4.2%) .49
Patients requiring intravenous
antibiotics
0 1 (4.2%) .49
PRBC transfusions 4 (16%) 1 (4.2%) .34
Platelet transfusions 2 (8.0%) 0 .49
Cardiac arrhythmias 2 (8%) 1 (4.2%) 1.00
Weight gain, median (range), lb 7 (0-24.0) 1 (0-10.0) .009
Weight gain, mean (range), % 3.67 (0-11.8) 1.27 (0-4.3) .001
Perimobilization mortalityy, n (%) 1 (4%) 0 (0%) .45
Hospitalization 7 (28%) 9 (32%) .47
Days of Hospitalization,
median (range)
1 (1-12) 1 (1-8) .70
Diarrhea 0 0 N/A
Hypotension 1 (4.2%) 0 .49
PRBC indicates packed red blood cells.
P values in bold text are statistically signiﬁcant.
* A single fever of 101F, or 2 temperatures more than 100.4F at least
1 hour apart in patient with an absolute neutrophil count of <500/mL.
y Mortality within 4 weeks of mobilization.RESULTS
Patient Characteristics
The baseline characteristics of 49 consecutive patients
included in this analysis are shown in Table 1. Twenty-ﬁve
patients underwent mobilization with G-CSF alone (G
group), whereas 24 patients received G-CSF and plerixafor
mobilization (GþP group). The 2 groups did not differ
signiﬁcantly at baseline for patient gender, age, bonemarrow
plasmacytosis at diagnosis, Karnofsky performance score,
more than 3 organs involved, creatinine, and N-terminal pro-
brain natriuretic peptide level. Troponin T level was higher in
the G group (P <. 001), but the participants in the GþP group
were heavily pretreated (P < .001). Fifteen patients (60%) in
the G group were not pretreated, compared with only 1 pa-
tient (4.2%) in the GþP group (P < .001). Among the patients
receiving pre-auto HCTchemotherapies, more patients in the
GþP group had achieved at least a partial response before
mobilization (P < .001). Similarly prior bortezomib use was
signiﬁcantly higher in the GþP group but there was no dif-
ference in prior lenalidomide use.
Efﬁcacy Characteristics
The total CD34þ cell yield was signiﬁcantly higher in the
GþP group compared with the G group (median collection,
11.9  106 cells/kg versus 6.1  106 cells/kg, P < .001). To
account for differences in the number of collection days
across patients, we compared CD34þ cell collection on day 1
of apheresis only. Mobilization with plerixafor was associ-
ated with signiﬁcantly higher day 1 yield of CD34þ cells
(median, 7.1  106 CD34þcells/kg versus 3.6  106 CD34þ
cells/kg, P ¼ .012). There was no signiﬁcant difference be-
tween the 2 groups in terms of total number of apheresis
sessions performed (median apheresis sessions, 1 in each
group; mean, 1.8 in the G group versus 1.5 in the GþP group).
As shown in Table 2, signiﬁcantly more patients in the GþP
group were able to collect at least 5, or 10  106 CD34þ cells/
kg. Fifteen patients (62%) in the GþP group reached a target
collection (ie, 5  106 cells/kg) on day 1, compared with 11
patients (44%) in the G group (P ¼ .19).
Four patients (16%) in the G group did not mobilize at
least 2  106 CD34þ cells/kg (mobilization failure), whereas
no mobilization failures were seen in the GþP group. The 4
patients who had mobilization failure had a median of
.95  106 (range, .6 to 1.25) CD34þ cells/kg. All of these pa-
tients had more than 2 organs involved, including cardiac
and renal involvement, and 1 patient was previously treated
with lenalidomide. None of these patients had prior expo-
sure to radiation. Two patients did not undergo auto-HCT.
Remobilization attempt with G-CSF in 1 of these patients
was not successful. Among the 2 patients who met the study
deﬁnition of mobilization failure and went on to receive
high-dose therapy (HDT), 1 (with 1.25  106 CD34þ cells/kg
infused) failed to engraft and the other patient had neutro-
phil recovery (1.26  106 CD34þ cells/kg infused) but died
during the hospital stay from cardiac arrest. The median
number of G-CSF doses was signiﬁcantly lower in the GþP
group (median, 5 doses; range, 4 to 6 doses) compared with
the G group (median, 6 doses; range, 5 to 8 doses; P < .001).
Toxicity and Supportive Care
None of the patients in the G group and 1 patient in the
GþP group developed an episode of febrile neutropenia
(Table 3) and required hospitalization for intravenous anti-
biotics. The G group had signiﬁcantly higher weight gain in
pounds at the end of mobilization compared with the weight
Table 4
Transplantation Outcomes
Outcome G (n ¼ 25) GþP (n ¼ 24) P Value
Median CD34þ dose infused 5 (1.1-31.6) 5.7 (.2-14) .41
Median time to ANC
engraftment
14 (11-29) 13.5 (11-71) .36
Median time to platelet
engraftment
12.5 (3-78) 15.5 (1-96) .49
Twelve-month overall survival 68.4% 100% .28
Twelve-month progression-
free survival
68.4% 92.3% .06
Day þ15 ALC >500/mL
Yes 2 (8%) 3 (12.5%) .53
No 17 (68%) 16 (66%)
Time from diagnosis to
transplantation, median
(range), mo
5 (3-6.9) 10.1 (4.8-16) .25
ANC indicates absolute neutrophil count; ALC, absolute lymphocyte count.
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pounds [range, 0 to 24] versus 1 pound [range, 0 to 10];
P ¼ .009.) There was no signiﬁcant difference between the 2
groups in terms of cardiac arrhythmias and transfusion re-
quirements (Table 3). Seven patients (28%) in the G and 9
patients (37%) in the GþP group required hospitalization for
mobilization-related complications (P ¼ .47). The complica-
tions in the G group included heart failure exacerbation
(n ¼ 3), arrhythmia (n ¼ 2), hypotension (n ¼ 1), and
bleeding (n ¼ 1), whereas the indications for admission in
GþP group was exacerbation of heart failure (n ¼ 3),
arrhythmia (n ¼ 1), bleeding (n ¼ 1), hypotension (n ¼ 1),
nausea/diarrhea (n ¼ 2), and fever with neutropenia (n ¼ 1).
There was no signiﬁcant difference in the median duration of
hospitalization between the 2 groups;median duration 1 day
(range, 1 to 12) in the G group versus median duration 1 day
(range, 1 to 8) in the GþP group; P ¼ .70.
Engraftment Outcomes
Five patients in the GþP group and 6 patients in the G
group did not undergo auto-HCT. The reasons for the 5 GþP
group not undergoing auto-HCT included death after disease
progression (n ¼ 1), fatal intracranial hemorrhage (n ¼ 1),
and patient and/or physician preference (n ¼ 3). All 6 pa-
tients in G group not receiving auto-HCT died because of
progressive disease after HPC collection (including 2 patients
who met deﬁnition of mobilization failure).
Patients in the G group received amedian CD34þ cell dose
of 5  106/kg (range, 1.1 to 31.6/kg) versus 5.7  106/kg
(range, .2 to 14)/kg in the GþP group (P ¼ .41) (Table 4).
Median time to neutrophil engraftment was 14 days (range,
11 to 29) in the G group compared with amedian of 13.5 days
(range, 11 to 71) in the GþP group (P ¼ .36). Median time to
platelet engraftment was 12.5 days (range, 3 to 78) in G and
15.5 days (range, 1 to 96) in GþP group (P ¼ .49).
Overall Survival and Progression-free Survival
The median follow-up of survivors was 18.1 months.
Comparing overall survival at 12 months, there were 6 sur-
viving patients and 0 deaths in the GþP group, compared
with 13 surviving patients and 6 deaths in the G group.
Because no events were observed in the plerixafor group, the
Fisher exact test was used to compare overall survival at
12 months among those with at least 12 months of follow-
up. The 12-month overall survival was 68.4% (95% conﬁ-
dence interval [CI], 42.8% to 84.4%) in the G group, and 100%
(CI not estimable) in the GþP group (P ¼ .28). The 12-monthprogression-free survival was 68.4% (95% CI, 42.8% to 84.4%)
in the G group and 92.3% (95% CI, 56.6% to 98.9%) in the GþP
group (log-rank P ¼ .064). Peri-mobilization mortality
deﬁned as mortality within 4 weeks of mobilization
regardless of the etiology occurred in only 1 patient in G
group (4%) and none in the GþP group (P ¼ .45).
DISCUSSION
The morbidity and mortality associated with HPC mobi-
lization with chemotherapy-based and cytokine-only stra-
tegies in AL amyloidosis is a signiﬁcant clinical challenge. To
our knowledge, our study provides the ﬁrst analysis of
mobilization outcomes comparing PþG versus G only in
patients with AL amyloidosis. Our data suggest that when
compared with a G-CSFeonly strategy, the addition of pler-
ixafor provides a higher HPC mobilization yield. Further-
more, weight gain was signiﬁcantly lower and no
mobilization failures were seen with a plerixafor-based
approach.
Signiﬁcant morbidity, including deaths, have been re-
ported during or immediately after G-CSFebased mobiliza-
tion in AL amyloidosis patients [15-17]. In our study, no
deaths were reported during mobilization in either group,
and 1 death was reported in the peri-mobilization period in
the G group (Table 3). Patients in the G group had signiﬁ-
cantly higher weight gain compared with those in the GþP
group. Limited exposure to G-SCF might be a contributing
factor in minimizing weight gain in the GþP group; however,
other factors might have played the role. Signiﬁcant weight
gain during HPC collection has previously been shown to be
an independent predictor of mortality after auto-HCT in AL
patients [19].
Inter- and intralaboratory variations in CD34þ cell
enumeration are an often under-reported limitation of
studies looking at efﬁcacy of HPC mobilization. Several var-
iables are associated with signiﬁcant variations in enumer-
ated absolute CD34þ cell counts, including variability in
gating strategies, type of CD34 monoclonal antibody used,
type of ﬂow cytometer used, method of sample preparation,
and assay platform methodology. Limited data suggest [25]
that variability in CD34þ cell enumeration can be mini-
mized by training individual laboratories in employing a
speciﬁc enumeration method (eg, the commonly used In-
ternational Society of Hematotherapy and Graft Engineering
protocol, also employed at our institution).
More patients in the GþP group received induction
therapies before auto-HCT; this is a reﬂection of a shift in
institutional practice after 2009 to use bortezomib-based
regimens before auto grafting. Many patients in the G
group received either no treatment or a single agent, such as
dexamethasone, before the mobilization. The ability to
mobilize HPCs in AL amyloidosis is impaired by various fac-
tors, including, advanced age, degree of bone marrow plas-
macytosis, organ involvement by AL amyloid, and prior
therapies, speciﬁcally prior exposure to alkylating agents etc.
[26,27]. Four patients in the G group experienced mobiliza-
tion failure, whereas no collection failures were observed
after the addition of plerixafor to our mobilization algorithm.
In our study, no signiﬁcant difference was seen between the
2 groups in terms of patient age, degree of amyloid organ
involvement, pretransplantation bone marrow cellularity,
pretransplantation bone marrow plasmacytosis, and prior
lenalidomide exposure.
Patients with AL amyloidosis are inherently fragile owing
to amyloidotic organ involvement and are, thus, more prone
B. Dhakal et al. / Biol Blood Marrow Transplant 20 (2014) 1926e19311930to life-threatening therapy-related complications. The
transplantation-related mortality is higher in AL amyloidosis
than multiple myeloma (39% versus 5%) [17,28,29]. Mobili-
zation regimens may also inﬂuence the graft composition of
infused product for auto-HCT and these regimens may
determine lymphocyte recovery and eventual outcome
following auto-SCT [30]. Day 15 lymphocyte recovery was
the same between the 2 groups in our study, as shown in
Table 4. In our study, 13 patients did not undergo auto-SCT
for various reasons, as described above. Our study shows
that there is no difference in the transplantation outcomes
and in time to platelet and absolute neutrophil count
engraftment between the 2 groups. There is also no differ-
ence in the overall survival and the progression-free sur-
vivals at 12 months follow-up.
There are limited data regarding the safety and utility of
upfront mobilization with plerixafor in AL amyloidosis. To
our knowledge, only a single patient case report [31] has
described the use of plerixafor as upfront mobilization
strategy in AL amyloidosis. Use of plerixafor as a remobili-
zation strategy has previously demonstrated feasibility in AL
amyloidosis patients failing an initial mobilization attempt
with mostly cytokine-based approaches [32]. Although
plerixafor-based mobilization strategies are clearly effective
in patients with lymphoid malignancies and plasma cell
disorders, the cost of this agent remains the main barrier
against its routine use in HPC collection. In cost analysis
studies, including only myeloma patients treated with a
novel-induction agent, the average cost of upfront mobili-
zation with plerixafor has been shown to be signiﬁcantly
higher than nonplerixafor-containing approaches [33].
Several studies have shown the feasibility of a so-called just-
in-time approach, where plerixafor is added to G-CSF in only
those patients who are likely to fail mobilization based on
day 4 CD34þ peripheral blood count. It is probable that such
an approach may have lower costs; however, no published
data are available [34,35]. In our current study, cost data of 2
mobilization methods employed are not available.
In conclusion, our study demonstrates that plerixafor
combined with an abbreviated course of G-CSF is feasible in
AL-amyloidosis patients and associated with signiﬁcantly
higher CD34þ cell collection yield, signiﬁcant less weight
gain, no mobilization failure, and no peri-mobilization
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